<DOC>
	<DOCNO>NCT00030277</DOCNO>
	<brief_summary>RATIONALE : Highly focus ultrasound energy may able kill cancer cell heat tumor without affect surround tissue . PURPOSE : This phase I trial study focus ultrasound energy see well work treat patient locally recurrent prostate cancer .</brief_summary>
	<brief_title>High-Intensity Focused Ultrasound Treating Patients With Locally Recurrent Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine ability Sonablate focus ultrasound wave purpose selectively destroy prostate cancer tissue , resultant drop PSA level 0.5 ng/mL negative biopsy cancer cell , patient locally recurrent prostate cancer . OUTLINE : Patients stratify accord prior treatment failure ( brachytherapy v post-external beam radiotherapy ) . A probe insert rectum . High-intensity focus ultrasound ( HIFU ) energy use Sonablate system deliver prostate tissue approximately 2 hour . Patients residual cancer lesion ( biopsy ) , PSA great 0.5 ng/mL increase PSA level take 2 month apart , visible prostate tissue ultrasound , local distant metastasis day 90 undergo retreatment HIFU . Patients follow 2 , 14 , 30 , 90 , 180 day . PROJECTED ACCRUAL : A total 20 patient ( 10 per stratum ) accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm locally recurrent prostate cancer prior brachytherapy externalbeam radiotherapy initial diagnosis organconfined disease ( clinical stage T1 T2 ) Prostatic fossa biopsy positive cancer cell Gleason score great 7 PSA level 0.510 ng/mL Able adequately visualize local recurrence transrectal ultrasound image No prostate calcification great 5 mm No metastases bone scan PATIENT CHARACTERISTICS : Age : 40 80 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : No bleed disorder determine abnormal PT PTT Renal : No active urinary tract infection No history urinary bladder neck contracture Other : No prior allergy latex No Anesthesia Surgical Assignment ( ASA ) category IV great No interest future fertility No history inflammatory bowel disease No concurrent major nonmalignant debilitate illness No prior concurrent malignancy except skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy prostate cancer Chemotherapy : No prior chemotherapy prostate cancer Endocrine therapy : At least 3 month since prior hormonal therapy ( include finasteride ) prostate cancer Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics No prior radical prostatectomy No prior transurethral resection prostate No prior urethral stent No prior major rectal surgery Other : No prior thermotherapy No prior therapy prostate cancer No concurrent warfarin anticoagulant</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>